Cargando…
MYC-Driven Pathways in Breast Cancer Subtypes
The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618234/ https://www.ncbi.nlm.nih.gov/pubmed/28696357 http://dx.doi.org/10.3390/biom7030053 |
_version_ | 1783267143187431424 |
---|---|
author | Fallah, Yassi Brundage, Janetta Allegakoen, Paul Shajahan-Haq, Ayesha N. |
author_facet | Fallah, Yassi Brundage, Janetta Allegakoen, Paul Shajahan-Haq, Ayesha N. |
author_sort | Fallah, Yassi |
collection | PubMed |
description | The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance. Activation of MYC has been widely reported in breast cancer progression. Breast cancer is a complex heterogeneous disease and treatment options are primarily guided by histological and biochemical evaluations of the tumors. Based on biochemical markers, three main breast cancer categories are ER+ (estrogen receptor alpha positive), HER2+ (human epidermal growth factor receptor 2 positive), and TNBC (triple-negative breast cancer; estrogen receptor negative, progesterone receptor negative, HER2 negative). MYC is elevated in TNBC compared with other cancer subtypes. Interestingly, MYC-driven pathways are further elevated in aggressive breast cancer cells and tumors that display drug resistant phenotype. Identification of MYC target genes is essential in isolating signaling pathways that drive tumor development. In this review, we address the role of MYC in the three major breast cancer subtypes and highlight the most promising leads to target MYC functions. |
format | Online Article Text |
id | pubmed-5618234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56182342017-09-29 MYC-Driven Pathways in Breast Cancer Subtypes Fallah, Yassi Brundage, Janetta Allegakoen, Paul Shajahan-Haq, Ayesha N. Biomolecules Review The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance. Activation of MYC has been widely reported in breast cancer progression. Breast cancer is a complex heterogeneous disease and treatment options are primarily guided by histological and biochemical evaluations of the tumors. Based on biochemical markers, three main breast cancer categories are ER+ (estrogen receptor alpha positive), HER2+ (human epidermal growth factor receptor 2 positive), and TNBC (triple-negative breast cancer; estrogen receptor negative, progesterone receptor negative, HER2 negative). MYC is elevated in TNBC compared with other cancer subtypes. Interestingly, MYC-driven pathways are further elevated in aggressive breast cancer cells and tumors that display drug resistant phenotype. Identification of MYC target genes is essential in isolating signaling pathways that drive tumor development. In this review, we address the role of MYC in the three major breast cancer subtypes and highlight the most promising leads to target MYC functions. MDPI 2017-07-11 /pmc/articles/PMC5618234/ /pubmed/28696357 http://dx.doi.org/10.3390/biom7030053 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Fallah, Yassi Brundage, Janetta Allegakoen, Paul Shajahan-Haq, Ayesha N. MYC-Driven Pathways in Breast Cancer Subtypes |
title | MYC-Driven Pathways in Breast Cancer Subtypes |
title_full | MYC-Driven Pathways in Breast Cancer Subtypes |
title_fullStr | MYC-Driven Pathways in Breast Cancer Subtypes |
title_full_unstemmed | MYC-Driven Pathways in Breast Cancer Subtypes |
title_short | MYC-Driven Pathways in Breast Cancer Subtypes |
title_sort | myc-driven pathways in breast cancer subtypes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618234/ https://www.ncbi.nlm.nih.gov/pubmed/28696357 http://dx.doi.org/10.3390/biom7030053 |
work_keys_str_mv | AT fallahyassi mycdrivenpathwaysinbreastcancersubtypes AT brundagejanetta mycdrivenpathwaysinbreastcancersubtypes AT allegakoenpaul mycdrivenpathwaysinbreastcancersubtypes AT shajahanhaqayeshan mycdrivenpathwaysinbreastcancersubtypes |